ZN-c3 for Carcinoma

Phase-Based Estimates
Site 3401, Quebec City, Canada
Carcinoma+2 More
ZN-c3 - Drug
Eligible conditions

Study Summary

This study is evaluating whether a drug may help treat uterine cancer.

See full description

Eligible Conditions

  • Carcinoma
  • Cystadenocarcinoma, Serous
  • Uterine Serous Carcinoma

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether ZN-c3 will improve 1 primary outcome and 3 secondary outcomes in patients with Carcinoma. Measurement will happen over the course of 2 years.

2 years
To investigate the antitumor activity of ZN-c3 based on the objective response rate (ORR).
To investigate the antitumor clinical activity based on Duration of Response (DOR)
To investigate the antitumor clinical activity based on Progression-Free Survival (PFS)
To investigate the safety and tolerability of ZN-c3

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Trial Design

2 Treatment Groups

ZN-c3 Single Agent

This trial requires 110 total participants across 2 different treatment groups

This trial involves 2 different treatments. ZN-c3 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

ZN-c3 Single Agent
ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 2 years for reporting.

Closest Location

Site 3401 - Quebec City, Canada

Eligibility Criteria

This trial is for female patients aged 18 and older. You must have received 1 prior treatment for Carcinoma or one of the other 2 conditions listed above. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
A disease is said to be measurable if there is at least one lesion that can be accurately measured using the revised Response Evaluation Criteria in Solid Tumors (RECIST) Guideline version 1.1 criteria. show original
Girls or women aged 18 or older are able to give consent. show original
Recurrent or persistent USC.
Someone who is in good health, with no significant medical problems, would have an ECOG performance status of 0 show original
The patient has adequate hematologic and organ function. show original
Females who might become pregnant must use contraception starting before the first dose of ZN c3 and continuing until 90 days after the last dose. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes carcinoma?

Add answer

Carcinoma develops when cells undergo transformation. This depends partly on genetic factors, and partly on external influences. The environmental agents that initiate transformation have not yet been definitely identified. The risk factors for carcinoma of any type include advancing age and cigarette smoking.

Unverified Answer

What are common treatments for carcinoma?

Add answer

The number of available treatments is very vast, depending on the type of carcinoma and the type, severity, or stage of the disease. The following is a brief summary of the main treatments available for carcinoma.

Unverified Answer

What is carcinoma?

Add answer

Carcinoma is a cancer typically associated with cancer of the body or the cervix. Although the word ‘carcinoma’ only appears in medical dictionaries once a year, cancer is one of the most important diseases affecting the world’s population.

Unverified Answer

Can carcinoma be cured?

Add answer

Findings from a recent study implies that a low dose (5 Gy) is sufficient for treatment of carcinoma without a relapse and survival rate. However, low dose RT should not be applied to patients with a poor performance status.

Unverified Answer

How many people get carcinoma a year in the United States?

Add answer

Carcinoma a year is very rare in the United Kingdom or the United States. On the basis of the US national death register, one in 400,000 people in the United States dies each year aged 70 years or over from the cancer. On the basis of the UK national cancer register, one in 350 people in England dies from the cancer.

Unverified Answer

What are the signs of carcinoma?

Add answer

The signs of carcinoma include a mass or lump on the surface of the body, a mass in the lumen of the bladder, and a mass in the rectum.

Unverified Answer

What is the survival rate for carcinoma?

Add answer

The survival rate of the patients with carcinoma is 1% 5 years from the time of onset; 1% 3 years from the time of diagnosis; and 4% 5 years from the time of diagnosis. Data from a recent study support the notion that the time from symptom onset to death of patients with carcinoma is relatively distant and that the initial treatment could be considered to be effective.

Unverified Answer

How quickly does carcinoma spread?

Add answer

We conclude that there is increased spread of carcinoma at initial presentation over time, and this justifies early histopathological confirmation of carcinoma at diagnosis and close outpatient follow-up of patients with carcinoma.

Unverified Answer

What is the primary cause of carcinoma?

Add answer

In a population with no hereditary and non-environmental factors, the principal risk factor for carcinoma is smoking; this does not include secondhand or third hand smoking. Carcinoma can be prevented by the use of the WHO (World Health Organisation) recommendations.\n

Unverified Answer

Does zn-c3 improve quality of life for those with carcinoma?

Add answer

Zn-c3 is effective in improving HRQoL in patients with carcinoma. This improvement has been seen by the time the patient had reached the stage of advanced malignancy.

Unverified Answer

Is zn-c3 typically used in combination with any other treatments?

Add answer

Results from a recent clinical trial suggest that the use of Zn-C3 in combination with radiation or chemotherapy should be limited to local indications since its effects in a distant site(s) is not expected to improve disease-free survival, PFS, or OS.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma by sharing your contact details with the study coordinator.